logo
Mirion (NYSE:MIR) Delivers Strong Q4 Numbers, Stock Soars

Mirion (NYSE:MIR) Delivers Strong Q4 Numbers, Stock Soars

Yahoo11-02-2025

Radiation technology company Mirion (NYSE:MIR) reported revenue ahead of Wall Street's expectations in Q4 CY2024, with sales up 10.4% year on year to $254.3 million. Its non-GAAP profit of $0.17 per share was 15.1% above analysts' consensus estimates.
Is now the time to buy Mirion? Find out in our full research report.
Revenue: $254.3 million vs analyst estimates of $245 million (10.4% year-on-year growth, 3.8% beat)
Adjusted EPS: $0.17 vs analyst estimates of $0.15 (15.1% beat)
Adjusted EBITDA: $69.6 million vs analyst estimates of $65.16 million (27.4% margin, 6.8% beat)
Adjusted EPS guidance for the upcoming financial year 2025 is $0.48 at the midpoint, missing analyst estimates by 3.3%
EBITDA guidance for the upcoming financial year 2025 is $222.5 million at the midpoint, below analyst estimates of $224.2 million
Operating Margin: 11.4%, up from 5.8% in the same quarter last year
Free Cash Flow Margin: 19.3%, down from 23.9% in the same quarter last year
Market Capitalization: $3.37 billion
'We are pleased to report record 2024 performance, with good momentum continuing into 2025,' commented Mirion's Chief Executive Officer Thomas Logan.
With its monitoring devices installed on spacecraft, Mirion (NYSE:MIR) offers radiation technology to government agencies, healthcare providers, and industrial companies.
Measurement and inspection instrument companies may enjoy more steady demand because products such as water meters are non-discretionary and mandated for replacement at predictable intervals. In the last decade, digitization and data collection have driven innovation in the space, leading to incremental sales. But like the broader industrials sector, measurement and inspection instrument companies are at the whim of economic cycles. Interest rates, for example, can greatly impact civil, commercial, and residential construction projects that drive demand.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last three years, Mirion grew its sales at a decent 8.8% compounded annual growth rate. Its growth was slightly above the average industrials company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within industrials, a stretched historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Mirion's annualized revenue growth of 9.5% over the last two years aligns with its three-year trend, suggesting its demand was stable.
This quarter, Mirion reported year-on-year revenue growth of 10.4%, and its $254.3 million of revenue exceeded Wall Street's estimates by 3.8%.
Looking ahead, sell-side analysts expect revenue to grow 4.4% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and implies its products and services will see some demand headwinds.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Although Mirion was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 1.7% over the last five years. Unprofitable industrials companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle.
Looking at the trend in its profitability, Mirion's operating margin decreased by 7.6 percentage points over the last five years. The company's performance was poor no matter how you look at it - it shows operating expenses were rising and it couldn't pass those costs onto its customers.
This quarter, Mirion generated an operating profit margin of 11.4%, up 5.6 percentage points year on year. The increase was solid, and since its operating margin rose more than its gross margin, we can infer it was recently more efficient with expenses such as marketing, R&D, and administrative overhead.
Revenue trends explain a company's historical growth, but the change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Mirion's EPS grew at an unimpressive 5.3% compounded annual growth rate over the last two years, lower than its 9.5% annualized revenue growth. However, its operating margin actually expanded during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.
Diving into the nuances of Mirion's earnings can give us a better understanding of its performance. A two-year view shows Mirion has diluted its shareholders, growing its share count by 16.5%. This dilution overshadowed its increased operating efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
In Q4, Mirion reported EPS at $0.17, up from $0.15 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Mirion to perform poorly. Analysts forecast its full-year EPS of $0.41 will hit $0.48.
We were impressed by how significantly Mirion blew past analysts' revenue expectations this quarter. We were also glad its EBITDA outperformed Wall Street's estimates. On the other hand, its full-year EBITDA guidance slightly missed. Zooming out, we think this was a good quarter with some key areas of upside. The stock traded up 6% to $17.15 immediately following the results.
Indeed, Mirion had a rock-solid quarterly earnings result, but is this stock a good investment here? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

Yahoo

time43 minutes ago

  • Yahoo

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio

Newsmax Stock: A Cautionary Tale for IPO Investors?
Newsmax Stock: A Cautionary Tale for IPO Investors?

Yahoo

time43 minutes ago

  • Yahoo

Newsmax Stock: A Cautionary Tale for IPO Investors?

Newsmax conducted its initial public offering at the end of March. Its share price has seen massive upward and downward movements. Investors can glean important lessons. 10 stocks we like better than Newsmax › Initial public offerings (IPOs) can get a lot of attention from the press and investors. This is the first time the public can buy shares in a company, and the share price can move up or down quickly. Newsmax (NYSE: NMAX) completed its IPO at the end of March. In the company's short life as a public company, the share price has been on a wild ride. It's good to take a look at the events and glean lessons. Perhaps it can even serve as a cautionary tale for the next flashy IPO that captures people's attention. Newmax's IPO raised $75 million by selling 7.5 million shares at $10. However, most investors weren't able to purchase shares at that price. On the stock's first day of trading, the share price shot up to close at $83.51. The following day, April Fool's Day, the shares closed at $233. There's no reliable way to predict short-term share price movements, however. Those who feared missing out and jumped in at these elevated prices have seen a massive downslide. The share price closed at $16.19 on June 5. A key lesson is not to buy into a stock's hype merely because the price has gone up a lot. Granted, it's not easy to ignore the hype and massive price movements. However, the best investing strategy is to look at the business and assess its long-term prospects. A media company, Newsmax generated more than three-quarters of its revenue from its broadcasting business. This includes cable channels and a streaming service that produces news and other content. Newsmax has a history of producing losses, however. Last year, the company lost $72.2 million compared to losses of $30.4 million and $41.8 million in 2022 and 2023, respectively. The wider losses came despite revenue increasing from $35.7 million to $171 million during this time. The company reported first-quarter results in May that showed a $17.2 million loss. Granted, it's heading in the right direction since that's narrower than the $50.7 million loss a year ago. While it's positive to produce revenue gains, profitability is what counts. When looking at newly public companies, ideally, investors should see them operating in the black. That's particularly true for Newsmax given it faces large and well-entrenched competitors. Newsmax currently has a $1.5 billion market capitalization. However, when the stock price reached $233, its market cap was about $21 billion. That might not mean much in isolation. But putting the figure into context could send a warning signal. Since the company doesn't report a profit, investors can't use the price-to-earnings (P/E) ratio. However, you can look at price-to-sales (P/S). Newmax's 2024 sales were $171 million in 2024. Dividing the $21 billion market cap by the sales figure equals a P/S multiple of 122 after its second day of trading. The company's revenue grew by 26% in 2024, but that valuation still seems excessive. The shares currently trade at a P/S ratio of 9. The Russell 2000 index, which encompasses small capitalization stocks, typically has a P/S ratio of about 1 to 2. There should be a compelling reason why a stock has a so much higher valuation than the benchmark index. It's natural to forget about unpleasant experiences. But you need to remember so you can learn and become better-educated investors. The next time you hear about a high-flying IPO, think about Newsmax and whether people are making short-term trades or investing because they believe the company has strong long-term fundamentals. After all, it's wise to think about investing as a marathon rather than a sprint. Before you buy stock in Newsmax, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Newsmax wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Newsmax Stock: A Cautionary Tale for IPO Investors? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

UnitedHealth Group received multiple bids for Latin American operations
UnitedHealth Group received multiple bids for Latin American operations

Yahoo

time43 minutes ago

  • Yahoo

UnitedHealth Group received multiple bids for Latin American operations

-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store